What does Groupement Radiothérapie Hématologie Oncologie do?

Groupement Radiothérapie Hématologie Oncologie is a hospital in Brussel. Non-profit, started on 17 March 1994.

What is the address of Groupement Radiothérapie Hématologie Oncologie?

The registered office of Groupement Radiothérapie Hématologie Oncologie is located at Kruidtuinlaan 32, 1000 Brussel.

Is Groupement Radiothérapie Hématologie Oncologie still active?

Yes. According to the CBE (2 November 2026) Groupement Radiothérapie Hématologie Oncologie is active, legal situation “Normale toestand”, started on 17 March 1994.

Is Groupement Radiothérapie Hématologie Oncologie registered on Peppol?

No, Groupement Radiothérapie Hématologie Oncologie is currently not registered on the Peppol network.

Is Groupement Radiothérapie Hématologie Oncologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 March 1994; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did Groupement Radiothérapie Hématologie Oncologie make in 2025?

Groupement Radiothérapie Hématologie Oncologie recorded a loss after taxes of € 248,159 in financial year 2025.

What is the revenue of Groupement Radiothérapie Hématologie Oncologie?

As a small company, Groupement Radiothérapie Hématologie Oncologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -237,086.

Groupement Radiothérapie Hématologie Oncologie (Non-profit)

Q: What is the enterprise number of Groupement Radiothérapie Hématologie Oncologie?

The enterprise number of Groupement Radiothérapie Hématologie Oncologie is BE0452611502.

Q: When was Groupement Radiothérapie Hématologie Oncologie founded?

Groupement Radiothérapie Hématologie Oncologie was founded on 17 March 1994.

Q: Who are the directors of Groupement Radiothérapie Hématologie Oncologie?

According to the 2025 annual accounts, the directors of Groupement Radiothérapie Hématologie Oncologie are: Deborah BAUWENS, Sabine MARICHAL, Sophie CVILIC.

Dossier Groupement Radiothérapie Hématologie Oncologie, printed on 3 November 2026 from databakkes.be/en/0452611502/groupement-radiotherapie-hematologie-oncologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Busy address KBO

20 other companies have their registered office at the same address; threshold 10.
Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

Groupement Radiothérapie Hématologie Oncologie from Brussel, company number BE0452611502, closed financial year 2025 with a result of € -248,159 after tax. For that financial year Groupement Radiothérapie Hématologie Oncologie recorded a gross margin of € -237,086 and equity of € 1.4 million. Compared with financial year 2024, the result moved from € -28,586 to € -248,159. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.

What it is worth Healthy

€ 1.4 million

▼ 15% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -248,159

▼ 768 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 804,157

▼ 13% vs 2024

Cash and bank balances on the last day of the fiscal year.

People and assets in 2025

Vehicles and equipment

€ 13,881

▼ 37% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 2,785

▲ € 2,263 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -90,709 Gross margin 2022: € -90,709 First fiscal year in the series	€ -218,285 Gross margin 2023: € -218,285 ▼ € 127,576 vs 2022 (€ -90,709) Unfavourable step	€ -19,307 Gross margin 2024: € -19,307 ▲ € 198,979 vs 2023 (€ -218,285) Favourable step	€ -237,086 Gross margin 2025: € -237,086 ▼ € 217,779 vs 2024 (€ -19,307) Unfavourable step	▼ € 217,779
Profit after taxes	€ -93,163 Profit after taxes 2022: € -93,163 First fiscal year in the series	€ -229,251 Profit after taxes 2023: € -229,251 ▼ € 136,089 vs 2022 (€ -93,163) Unfavourable step	€ -28,586 Profit after taxes 2024: € -28,586 ▲ € 200,666 vs 2023 (€ -229,251) Favourable step	€ -248,159 Profit after taxes 2025: € -248,159 ▼ € 219,574 vs 2024 (€ -28,586) Unfavourable step	▼ € 219,574
Equity	€ 1,861,640 Equity 2022: € 1,861,640 First fiscal year in the series	€ 1,632,388 Equity 2023: € 1,632,388 ▼ 12% vs 2022 (€ 1,861,640) Unfavourable step	€ 1,603,802 Equity 2024: € 1,603,802 ▼ 2% vs 2023 (€ 1,632,388) Unfavourable step	€ 1,355,643 Equity 2025: € 1,355,643 ▼ 15% vs 2024 (€ 1,603,802) Unfavourable step	▼ 15%
Total debts	€ 112 Total debts 2022: € 112 First fiscal year in the series	€ 7,569 Total debts 2023: € 7,569 ▲ € 7,456 vs 2022 (€ 112) Unfavourable step	€ 522 Total debts 2024: € 522 ▼ 93% vs 2023 (€ 7,569) Favourable step	€ 22,785 Total debts 2025: € 22,785 ▲ € 22,263 vs 2024 (€ 522) Unfavourable step	▲ € 22,263
Cash	€ 966,588 Cash 2022: € 966,588 First fiscal year in the series	€ 761,171 Cash 2023: € 761,171 ▼ 21% vs 2022 (€ 966,588) Unfavourable step	€ 922,013 Cash 2024: € 922,013 ▲ 21% vs 2023 (€ 761,171) Favourable step	€ 804,157 Cash 2025: € 804,157 ▼ 13% vs 2024 (€ 922,013) Unfavourable step	▼ 13%
Retained profit	€ 1,861,640 Retained profit 2022: € 1,861,640 First fiscal year in the series	€ 1,632,388 Retained profit 2023: € 1,632,388 ▼ 12% vs 2022 (€ 1,861,640) Unfavourable step	€ 1,603,802 Retained profit 2024: € 1,603,802 ▼ 2% vs 2023 (€ 1,632,388) Unfavourable step	€ 1,355,643 Retained profit 2025: € 1,355,643 ▼ 15% vs 2024 (€ 1,603,802) Unfavourable step	▼ 15%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 5,759 Bank debt 2023: € 5,759 Unchanged (€ 0) Unfavourable step	€ 0 Bank debt 2024: € 0 ▼ 100% vs 2023 (€ 5,759) Favourable step	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 1,861,752 Balance sheet total 2022: € 1,861,752 First fiscal year in the series	€ 1,639,957 Balance sheet total 2023: € 1,639,957 ▼ 12% vs 2022 (€ 1,861,752) Unchanged	€ 1,604,324 Balance sheet total 2024: € 1,604,324 ▼ 2% vs 2023 (€ 1,639,957) Unchanged	€ 1,378,428 Balance sheet total 2025: € 1,378,428 ▼ 14% vs 2024 (€ 1,604,324) Unchanged	▼ 14%

Key figures of Groupement Radiothérapie Hématologie Oncologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Groupement Radiothérapie Hématologie Oncologie?

What happened at Groupement Radiothérapie Hématologie Oncologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 22, 2026 New annual accounts for financial year 2025: loss of € 248,159. Source: NBB ↗
Mar 17, 1994 Start of the company according to the CBE. KBO

In short

From € 93,163 loss in 2022 to € 248,159 loss in 2025.

Original PDFs at the National Bank ↗

Management

Deborah BAUWENS Sabine MARICHAL Sophie CVILIC

Groupement Radiothérapie Hématologie Oncologie

DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ

Behind Groupement Radiothérapie Hématologie Oncologie are Deborah BAUWENS, Sabine MARICHAL and Sophie CVILIC. Sabine MARICHAL is also behind DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ.

Directors

According to the 2025 annual accounts

Deborah BAUWENS

Director

Sabine MARICHAL

Director

Also active at: DR. MARICHAL, ONCO-HÉMATOLOGIE ET SANTÉ

Sophie CVILIC

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Kruidtuinlaan 32

1000 Brussel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.

All companies at this address →

Kliniek Sint-Jan

€ 233.8 million revenue · 2025

NEURO SAINT - JEAN

SERVICE D'ANESTHESIOLOGIE

€ -6,876 gross margin · 2025

PALIATIEVE ZORGEN SINT JAN - SOINS PALLIATIFS SAINT JEAN

OB - GYN ST. JEAN

€ 8,262 gross margin · 2025

+15 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0452.611.502

VAT number

BE 0452.611.502

Registered office

Kruidtuinlaan 32, 1000 Brussel

Names & denominations

Groupement Radiothérapie Hématologie Oncologie · R.H.O.

Enterprise type

Rechtspersoon

Legal form

Non-profit association

Legal situation

Normale toestand

Start date

17 March 1994

Peppol

Not registered

Activities · NACE

Activiteiten van algemene ziekenhuizen, muv geriatrische en gespecialiseerde ziekenhuizen

Ziekenhuizen

View on CBE Public ↗ Annual accounts (NBB) ↗

Groupement Radiothérapie Hématologie Oncologie

Warning lights

Financials

What happened to Groupement Radiothérapie Hématologie Oncologie?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions